Kristin Brooks, Contract Pharma04.27.20
The Covid-19 pandemic is having a significant impact on CROs and clinical trials resulting in trial suspensions, terminations and delays. The global crisis has also stressed the need for virtual trials leveraging technology and software solutions. Increased adoption of eClinical solutions, Artificial Intelligence, machine learning-based platforms, and innovative trial designs, is expected to transform the CRO landscape over the next few years.
Pharma and biopharma investments in new and innovative therapies, such as regenerative medicine, is resulting in a flourish of R&D activity, along with higher reliance on outsourcing partners for drug development services.
Sponsors continue to seek out therapy area expertise and services as needed. Speed and cost remain strong motivators for outsourcing in today’s market, along with increasing complexity of trials and higher regulatory hurdles. The uncertainty surrounding the global economy is likely to lead to le
FREE SUBSCRIPTION
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
